-
CDE issues 3 guiding principles for clinical trial design of new drugs for advanced colorectal cancer
Time of Update: 2022-01-27
On December 29, CDE's official website released 3 guidelines, covering clinical trial design of new drugs for advanced colorectal cancer, extended cohort research technology for first-in-human trials of antitumor drugs, and single and multiple dose-escalation pharmacokinetics of innovative chemical drugs.
-
In 2022, the scale of my country's biopharmaceutical market will exceed 4 trillion
Time of Update: 2022-01-27
Among them, a total of 20 new drugs participated in the National Medical Insurance Talk for the first time, including PARP inhibitors, BTK inhibitors, ALK inhibitors, ADC drugs, CAR-T therapy, etc.
-
At the beginning of 2022, there have been new changes in the executives of many pharmaceutical companies
Time of Update: 2022-01-27
Mike Hu also worked in Novartis, GlaxoSmithKline, Jazz Pharmaceuticals and other companies, and held a number of preclinical research and clinical development leadership positions .
Jie Jack Li (Li Jie) as the company's Chief Scientific Officer, taking overall responsibility for the company's global early stage research and development of new drugs .
-
How should pharmaceutical companies respond to the rise in the price of Chinese herbal medicines?
Time of Update: 2022-01-27
In addition to the method of stocking up in advance, some pharmaceutical companies have taken measures such as improving production technology, developing their own medicinal material planting bases, upgrading equipment, improving processes, and centralized procurement to achieve the purpose of reducing costs and increasing efficiency and controlling production.
-
Qinghai Province issued a drug quality sampling inspection information notice that 1 batch of drugs did not meet the regulations
Time of Update: 2022-01-27
On December 29, the Qinghai Provincial Food and Drug Administration issued an announcement stating that in order to strengthen drug quality supervision and ensure the safety of public medication, according to the Qinghai Provincial Drug Sampling Plan in 2021, it organized drug production (preparation) and operating enterprises in the province to conduct drug quality inspections.
-
The first brother of the pharmaceutical stock flashed a market value of over 40 billion!
Time of Update: 2022-01-27
As of the close on December 31, 2021, 14 pharmaceutical stocks including Mindray Medical, WuXi AppTec, Hengrui Medicine, and Pien Tze Huang have a market value of 100 billion yuan .
-
In 2021, the A-share market value of the pharmaceutical and biological industry will exceed the 8 trillion mark
Time of Update: 2022-01-27
From the perspective of the market value of major pharmaceutical and biological companies, according to the author's incomplete statistics, as of the end of 2021, Mindray Medical, WuXi AppTec, Hengrui Medicine, Ai There are at least 13 pharmaceutical companies including Er Ophthalmology, Zhifei Bio, Pien Tze Huang, Fosun Pharma, Pharmaron, Amic, Tigermed, Changchun High-tech, Yunnan Baiyao, and BeiGene .
-
Another batch of pharmaceutical companies has stopped production and cancelled!
Time of Update: 2022-01-27
For example, on December 31, 2021, the Hunan Provincial Food and Drug Administration issued an announcement saying that according to the application of Huaihua Longyuan Pharmaceutical Co.
. On December 21, the Jiangsu Provincial Food and Drug Administration issued a notice on unannounced inspections of medical device manufacturers .
-
In 2022, a group of pharmaceutical companies will accelerate their exit!
Time of Update: 2022-01-27
On the same day, according to a production suspension notice issued by the Anhui Provincial Food and Drug Administration, Anhui Jucao Chinese Herbal Pieces Co.
-
Under the big wave of China's innovative drugs, 4 types of companies are optimistic
Time of Update: 2022-01-27
In recent years, under the multiple favorable resonances such as the frequent introduction of policies, the influx of talents, the increase in research and development, and the increase in capital, China's innovative drug industry has developed rapidly .
-
With the continuous favorable policies in the field of traditional Chinese medicine, how should pharmaceutical companies seize the opportunity?
Time of Update: 2022-01-27
Subsequently, on December 30, the National Medical Security Administration and the State Administration of Traditional Chinese Medicine jointly issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine", clarifying that general TCM medical services can continue to be paid by the project, and TCM medical institutions can For the time being, the payment by disease diagnosis-related group (DRG) is not implemented.
-
In 2022, the domestic PD-1 market competition will further intensify
Time of Update: 2022-01-27
It is reported that there are currently as many as 6 domestic PD-1s listed in China, namely Hengrui's camrelizumab, BeiGene's tislelizumab, Innovent's sintilimab, Jun Shibi's toripalimab, Kangfang Bio's piamplimumab and Yuheng Bio's sapalimab, of which the latter two are newly approved products in 2021, while the first four are Has entered medical insurance through price reduction .
-
The State Food and Drug Administration issued 14 guidelines for registration review including fluorescence immunochromatography analyzers
Time of Update: 2022-01-27
48 of the State Administration for Market Regulation), the State Drug Administration organized and formulated 14 guiding principles for registration and review of fluorescence immunochromatography analyzers (see attachments).
Guidelines for the registration and review of fluorescence immunochromatography analyzers 2.
-
Over 2,000 institutions gathered to investigate this medical equipment giant!
Time of Update: 2022-01-27
79 billion yuan, a year-on-year increase of about 19%, and R&D investment accounted for 9.
From the perspective of the research content, the institutions are mainly concerned about the core competitiveness of Haipeptide Biology and the technology of newly launched products.
-
202 large varieties have met the conditions for national picking (list attached)
Time of Update: 2022-01-26
com, in 2020, the sales of tenofovir alafenamide in China's public medical institutions exceeded 370 million yuan, a year-on-year increase of 860.
-
Generic drug of Shengshi Taike Teriflunomide approved for the treatment of multiple sclerosis
Time of Update: 2022-01-26
According to the priority review announcement of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, the approved indication for this drug is relapsing multiple sclerosis .
Retrieved Jan 5, 2022, from https:// Blockbuster | Aubajie®—the first oral drug for multiple sclerosis approved in China.
-
In 2022, pharmaceutical companies will still have a strong demand for the recruitment of pharmaceutical representatives
Time of Update: 2022-01-26
Industry analysts believe that judging from the current recruitment positions of major pharmaceutical companies, it can be clearly found that pharmaceutical companies are indeed paying more attention to the transmission of product information and improving their sensitivity to the market .
-
Treat early breast cancer!
Time of Update: 2022-01-26
TextPharmaceutical GuanlanOn January 6, Eli Lilly and Company announced that its new anti-tumor drug Abeccil (trade name: Weizhe) was approved by China's National Medical Products Administration (NMPA) in combination with tamoxifen or aromatized Endocrine therapy such as enzyme inhibitors is suitable for adjuvant therapy in adult patients with HR-positive, HER2-negative, lymph node-positive, high recurrence risk and Ki-67≥20% early breast cancer .
-
Deploying traditional Chinese medicine, pharmaceutical companies are constantly making new moves!
Time of Update: 2022-01-26
Through the integration and innovation of "digital technology + traditional Chinese medicine", it is expected to create a new format for the digital development of the traditional Chinese medicine industry in the future .
-
140 OTC drugs sold over 100 million!
Time of Update: 2022-01-26
com, there are 4 traditional Chinese medicine OTC products with sales expected to exceed 1 billion yuan in 2021 in Chinese urban physical pharmacy terminals: Ganmaoling Granules and Jianwei Xiaoshi Tablets have increased sales compared with 2020, while Banlangen The sales of Granules and Lianhua Qingwen Capsules rose sharply in 2020 due to the epidemic, and returned to normal levels in 2021 .
